Rahbar Saadat Yalda, Abbasi Amin, Hejazian Seyyed Sina, Hekmatshoar Yalda, Ardalan Mohammadreza, Farnood Farahnoosh, Zununi Vahed Sepideh
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC Nephrol. 2025 Mar 11;26(1):133. doi: 10.1186/s12882-025-04057-8.
In 2008, the Society on Sarcopenia, Cachexia, and Wasting Disorders introduced a generic definition for all types of cachexia: "a complex metabolic syndrome associated with the underlying illness characterized by a loss of muscle, with or without fat loss". It is well-known that the presence of inflammatory burden in end-stage renal disease (ESRD) patients may lead to the evolution of cachexia. Since the etiology of cachexia in chronic kidney disease (CKD) is multifactorial, thus the successful treatment must involve several concomitant measures (nutritional interventions, appetite stimulants, and anti-inflammatory pharmacologic agents) to provide integrated effective therapeutic modalities to combat causative factors and alleviate the outcomes of patients. Given the high mortality rate associated with cachexia, developing new therapeutic modalities are prerequisite for ameliorating patients with CKD worldwide. The present review aims to discuss some therapeutic strategies and provide an update on advances in nutritional approaches to counteract cachexia.
2008年，肌肉减少症、恶病质及消瘦症学会对所有类型的恶病质给出了一个通用定义：“一种与基础疾病相关的复杂代谢综合征，其特征为肌肉丢失，伴或不伴有脂肪减少”。众所周知，终末期肾病（ESRD）患者体内炎症负担的存在可能会导致恶病质的进展。由于慢性肾脏病（CKD）恶病质的病因是多因素的，因此成功的治疗必须包括几种协同措施（营养干预、食欲刺激剂和抗炎药物），以提供综合有效的治疗方式来对抗致病因素并减轻患者的症状。鉴于与恶病质相关的高死亡率，开发新的治疗方式是改善全球CKD患者病情的先决条件。本综述旨在讨论一些治疗策略，并提供关于对抗恶病质的营养方法进展的最新情况。
